MA34735B1 - Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil - Google Patents

Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil

Info

Publication number
MA34735B1
MA34735B1 MA36010A MA36010A MA34735B1 MA 34735 B1 MA34735 B1 MA 34735B1 MA 36010 A MA36010 A MA 36010A MA 36010 A MA36010 A MA 36010A MA 34735 B1 MA34735 B1 MA 34735B1
Authority
MA
Morocco
Prior art keywords
tenofovir disoproxil
disoproxil fumarate
therapeutic compositions
rilpivirine hydrochloride
hydrochloride
Prior art date
Application number
MA36010A
Other languages
English (en)
Inventor
Reza Oliyai
Lauren Wiser
Mark Menning
Original Assignee
Janssen R & D Ireland
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34735(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R & D Ireland, Gilead Sciences Inc filed Critical Janssen R & D Ireland
Publication of MA34735B1 publication Critical patent/MA34735B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des comprimés multicouches qui contiennent un hydrochlorure de rilpivirine, un emtricitabine et un fumarate de ténofovir disoproxil. Les comprimés sont utilisés pour traiter le VIH.
MA36010A 2010-11-19 2013-06-14 Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil MA34735B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41560010P 2010-11-19 2010-11-19
PCT/US2011/061515 WO2012068535A1 (fr) 2010-11-19 2011-11-18 Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil

Publications (1)

Publication Number Publication Date
MA34735B1 true MA34735B1 (fr) 2013-12-03

Family

ID=45094284

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36010A MA34735B1 (fr) 2010-11-19 2013-06-14 Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil

Country Status (35)

Country Link
US (1) US10857102B2 (fr)
EP (2) EP2826466A1 (fr)
JP (2) JP2014500261A (fr)
KR (1) KR101923103B1 (fr)
CN (2) CN106511357A (fr)
AP (1) AP3816A (fr)
AR (2) AR084500A1 (fr)
AU (3) AU2011329642B2 (fr)
BR (1) BR112013012245B1 (fr)
CA (1) CA2818097C (fr)
CL (1) CL2013001402A1 (fr)
CO (1) CO6761300A2 (fr)
CR (1) CR20130293A (fr)
DK (1) DK2640362T4 (fr)
EA (2) EA201691695A1 (fr)
EC (2) ECSP13012700A (fr)
ES (1) ES2524408T5 (fr)
HK (2) HK1190064A1 (fr)
HR (1) HRP20140946T1 (fr)
IL (1) IL226300B (fr)
MA (1) MA34735B1 (fr)
ME (1) ME01980B (fr)
MX (1) MX347512B (fr)
MY (1) MY185604A (fr)
NZ (1) NZ610729A (fr)
PE (3) PE20140163A1 (fr)
PL (1) PL2640362T5 (fr)
PT (1) PT2640362E (fr)
RS (1) RS53691B1 (fr)
SG (3) SG190333A1 (fr)
SM (1) SMT201400150B (fr)
TW (1) TWI556840B (fr)
UA (1) UA114075C2 (fr)
WO (1) WO2012068535A1 (fr)
ZA (1) ZA201304481B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
ME01980B (fr) 2010-11-19 2015-05-20 Gilead Sciences Inc Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil
US8754065B2 (en) 2011-08-16 2014-06-17 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
CA2779052A1 (fr) * 2012-05-31 2013-11-30 Pharmascience Inc. Composition pharmaceutique d'antecavir et processus de fabrication
ES2926068T3 (es) 2012-12-21 2022-10-21 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
WO2015014737A1 (fr) * 2013-07-29 2015-02-05 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations pour comprimés multicouches comprenant du tenofovir et de l'entécavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (fr) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Dispersion solide amorphe comprenant du paclitaxel, comprimé la comprenant, et son procédé de préparation
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
CA2921336A1 (fr) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Formulations pharmaceutiques
KR20170003063A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
SG11201802983TA (en) 2015-11-09 2018-05-30 Gilead Sciences Inc Therapeutic compositions for treatment of human immunodeficiency virus
US20190060325A1 (en) * 2016-04-08 2019-02-28 Shionogi & Co., Ltd. Stabilized solid dosage form
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) * 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
US12011506B2 (en) 2017-06-30 2024-06-18 Viiv Healthcare Company Combination and uses and treatments thereof
CN111372592A (zh) 2017-12-07 2020-07-03 埃默里大学 N4-羟基胞苷及衍生物和与其相关的抗病毒用途
US20210000823A1 (en) * 2019-07-03 2021-01-07 Janssen Sciences Ireland Unlimited Company Methods of treating hiv
CN112137981A (zh) * 2020-11-02 2020-12-29 成都晶富医药科技有限公司 富马酸丙酚替诺福韦片及其制备工艺

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241625A (en) 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US20030124186A1 (en) 2001-11-27 2003-07-03 Hussain Munir A. Efavirenz tablet formulation having unique biopharmaceutical characteristics
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
EP1632232B3 (fr) 2004-09-02 2022-03-30 Janssen Pharmaceutica NV Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
PL1632232T6 (pl) 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP1933815A2 (fr) 2005-10-14 2008-06-25 Microdose Technologies Inc. Conditionnement pharmaceutique d'une combinaison posologique orale
SI2051703T1 (sl) 2005-12-14 2011-01-31 Cipla Ltd Farmacevtski sestavki, ki vsebujejo inhibitorje nukleotidne in nukleozidne reverzne transkriptaze (kot tenofovir in lamivudin) v različnih delih dozirne oblike
LT2487166T (lt) * 2007-02-23 2016-11-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
WO2008140461A1 (fr) 2007-05-16 2008-11-20 Fmc Corporation Forme solide
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
US20090270352A1 (en) 2007-05-22 2009-10-29 Ultimorphix Technologies B.V. Tenofovir Disoproxil Hemi-Fumaric Acid Co-Crystal
WO2009037449A1 (fr) 2007-09-18 2009-03-26 Cipla Limited Compositions pharmaceutiques solides comprenant un ou plusieurs inhibiteurs du virus de l'herpès et un ou plusieurs inhibiteurs de la transcriptase inverse
WO2009106960A2 (fr) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Compositions stables de lamivudine, de ténofovir et d'éfavirenz
SG190618A1 (en) 2008-05-02 2013-06-28 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
SG10201706215UA (en) 2009-02-06 2017-08-30 Gilead Sciences Inc Tablets for combination therapy
EP2480552B1 (fr) 2009-09-21 2016-11-09 Gilead Sciences, Inc. Analogues de carbanucléoside 2'-fluoro-substitués pour traitement antiviral
WO2011077100A1 (fr) 2009-12-24 2011-06-30 Cipla Limited Composition antirétrovirale
ME01980B (fr) 2010-11-19 2015-05-20 Gilead Sciences Inc Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil

Also Published As

Publication number Publication date
AU2011329642A1 (en) 2013-05-02
PL2640362T5 (pl) 2022-05-02
US20130243857A1 (en) 2013-09-19
CL2013001402A1 (es) 2013-12-27
AP2013006931A0 (en) 2013-06-30
CN103491948B (zh) 2016-11-02
HRP20140946T1 (hr) 2015-02-13
PL2640362T3 (pl) 2015-03-31
SMT201400150B (it) 2015-01-15
WO2012068535A1 (fr) 2012-05-24
CO6761300A2 (es) 2013-09-30
KR101923103B1 (ko) 2018-11-28
PE20211657A1 (es) 2021-08-24
EA201390651A1 (ru) 2013-11-29
KR20140037799A (ko) 2014-03-27
AR084500A1 (es) 2013-05-22
AR123409A2 (es) 2022-11-30
DK2640362T4 (da) 2022-03-07
ECSP19078196A (es) 2019-11-30
SG10201509521WA (en) 2015-12-30
JP2015131853A (ja) 2015-07-23
MY185604A (en) 2021-05-25
AU2016208417B2 (en) 2018-04-05
SG10201912527XA (en) 2020-02-27
TW201238612A (en) 2012-10-01
ZA201304481B (en) 2022-03-30
SG190333A1 (en) 2013-06-28
BR112013012245A2 (pt) 2016-08-09
CR20130293A (es) 2013-10-03
AU2018202635A1 (en) 2018-05-10
HK1206592A1 (en) 2016-01-15
EP2640362B2 (fr) 2021-12-01
CA2818097C (fr) 2019-07-30
CN103491948A (zh) 2014-01-01
HK1190064A1 (en) 2014-06-27
EA201691695A1 (ru) 2017-11-30
BR112013012245B1 (pt) 2022-09-27
TWI556840B (zh) 2016-11-11
MX347512B (es) 2017-04-28
PE20140163A1 (es) 2014-02-08
JP2014500261A (ja) 2014-01-09
ES2524408T5 (es) 2022-04-25
RS53691B1 (en) 2015-04-30
US10857102B2 (en) 2020-12-08
NZ610729A (en) 2015-10-30
UA114075C2 (xx) 2017-04-25
JP6138851B2 (ja) 2017-05-31
ME01980B (fr) 2015-05-20
MX2013005669A (es) 2013-11-04
IL226300B (en) 2019-05-30
PE20170521A1 (es) 2017-05-27
AU2011329642B2 (en) 2016-08-11
ECSP13012700A (es) 2013-08-30
DK2640362T3 (en) 2014-12-01
EP2640362A1 (fr) 2013-09-25
AP3816A (en) 2016-09-30
CA2818097A1 (fr) 2012-05-24
EP2826466A1 (fr) 2015-01-21
ES2524408T3 (es) 2014-12-09
EP2640362B1 (fr) 2014-09-10
AU2016208417A1 (en) 2016-08-18
PT2640362E (pt) 2014-11-28
EA025852B1 (ru) 2017-02-28
CN106511357A (zh) 2017-03-22

Similar Documents

Publication Publication Date Title
MA34735B1 (fr) Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil
SA519402217B1 (ar) مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون
JOP20190041B1 (ar) مركبات وتركيبات كمثبطات لمستقبلات شبيهة بالتول إندوسومية
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
MA43187A (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MA44890A (fr) Compositions comprenant des souches bactériennes
MA44322A (fr) Compositions comprenant des souches bactériennes
MA42471A (fr) Compositions comprenant des souches bactériennes
MY191357A (en) Sustained-release dosage forms of ruxolitinib
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA37840A3 (fr) Immunoconjugués comprenant des anticorps anti-cd79b
MX2017016802A (es) Formulaciones farmaceuticas.
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
RS65386B1 (sr) Benzoazepinski analozi kao sredstva za inhibiciju brutonove tirozin kinaze
MX2018006773A (es) Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina.
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
CY1118255T1 (el) Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
FR2990843B1 (fr) Dispositif d'attache implantable, implant pour le traitement des prolapsus de la statique pelvienne comportant un tel dispositif et kit comprenant ledit dispositif.
JOP20170198A1 (ar) صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين
CY1116115T1 (el) Θεραπευτικες συνθεσεις οι οποιες αποτελουνται απο ριλπιβιρινη hcl και δισοπροξιλικη φουμαρικη τενοφοβιρη
MA46980A (fr) Compositions comprenant des souches bactériennes
MA45476A (fr) Compositions comprenant des souches bactériennes
CR20170601A (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina